Qingdao Baheal Medical Inc
SZSE:301015
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Qingdao Baheal Medical Inc
Cash & Cash Equivalents
Qingdao Baheal Medical Inc
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Q
|
Qingdao Baheal Medical Inc
SZSE:301015
|
Cash & Cash Equivalents
ÂĄ984.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
Sinopharm Group Co Ltd
HKEX:1099
|
Cash & Cash Equivalents
ÂĄ34.4B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
9%
|
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
Cash & Cash Equivalents
ÂĄ27.5B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
Jointown Pharmaceutical Group Co Ltd
SSE:600998
|
Cash & Cash Equivalents
ÂĄ8.8B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
16%
|
|
C
|
China National Medicines Corp Ltd
SSE:600511
|
Cash & Cash Equivalents
ÂĄ10.9B
|
CAGR 3-Years
28%
|
CAGR 5-Years
23%
|
CAGR 10-Years
29%
|
Huadong Medicine Co Ltd
SZSE:000963
|
Cash & Cash Equivalents
ÂĄ4.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
See Also
What is Qingdao Baheal Medical Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
984.6m
CNY
Based on the financial report for Dec 31, 2023, Qingdao Baheal Medical Inc's Cash & Cash Equivalents amounts to 984.6m CNY.
What is Qingdao Baheal Medical Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
14%
Over the last year, the Cash & Cash Equivalents growth was 25%. The average annual Cash & Cash Equivalents growth rates for Qingdao Baheal Medical Inc have been 1% over the past three years , 14% over the past five years .